Lyell Stock

lyellbiotech.comBioTechFounded: 2018Funding to Date: $358MM

Lyell Immunopharma is a developer of curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors.

Register for Details

For more details on financing and valuation for Lyell, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Akira Matsuno
Chief Financial Officer & Head of Corporate Development
Premal Patel MD
Chief Medical Officer
Richard Klausner MD
Founder, President, Board Member & Chief Executive Officer

Board Members

Cathy Friedman
Hans Bishop
Richard Klausner MD
Robert Nelsen
ARCH Venture Partners

Other companies like Lyell in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$197.73MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM